search
Back to results

Effect of Lidocaine Plus Dexmedetomidine Infusion on PONV

Primary Purpose

Lidocaine, Dexmedetomidine, Nausea and Vomiting, Postoperative

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
lidocaine and dexmedetomidine IV
saline IV
Sponsored by
Xu Siqi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Lidocaine focused on measuring Lidocaine, Dexmedetomidine, Postoperative nausea and vomiting, laparoscopic hysterectomy

Eligibility Criteria

40 Years - 55 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) physical statusⅠand Ⅱ
  • Aged 40-55 years
  • Scheduled for elective laparoscopic hysterectomy

Exclusion Criteria:

  • History of allergy to local anesthetics
  • Severe respiratory disease
  • Renal or hepatic insufficiency
  • History of preoperative opioids medication and psychiatric
  • preoperative bradycardia
  • preoperative atrioventricular block
  • Subjects who experienced severe hypotension (mean arterial pressure [MAP] <60 mmHg) or bradycardia (heart rate [HR] <40 bpm), urticaria, or arrhythmia during lidocaine and dexmedetomidine infusion period

Sites / Locations

  • Department of Anqing Hospital Anesthesiology

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Effect of IV lidocaine and dexmedetomidine on PONV

Effect of IV saline on PONV

Arm Description

Outcomes

Primary Outcome Measures

postoperative nausea
Our primary outcome was the incidence of nausea during the 0-2 hours after surgery
postoperative nausea
Our primary outcome was the incidence of nausea during the 2-24 hours after surgery
postoperative nausea
Our primary outcome was the incidence of nausea during the 24-48 hours after surgery
postoperative vomiting
Our primary outcome was the incidence of vomiting during the 0-2 hours after surgery
postoperative vomiting
Our primary outcome was the incidence of vomiting during the 2-24 hours after surgery
postoperative vomiting
Our primary outcome was the incidence of vomiting during the 24-48 hours after surgery
postoperative nausea and vomiting (PONV)
Our primary outcome was the incidence of PONV during the 0-2 hours after surgery
postoperative nausea and vomiting (PONV)
Our primary outcome was the incidence of PONV during the 2-24 hours after surgery
postoperative nausea and vomiting (PONV)
Our primary outcome was the incidence of PONV during the 24-48 hours after surgery

Secondary Outcome Measures

Full Information

First Posted
December 20, 2018
Last Updated
January 7, 2019
Sponsor
Xu Siqi
search

1. Study Identification

Unique Protocol Identification Number
NCT03788018
Brief Title
Effect of Lidocaine Plus Dexmedetomidine Infusion on PONV
Official Title
Effect of Intravenous Lidocaine Combined With Dexmedetomidine on Postoperative Nausea and Vomiting After Laparoscopic Hysterectomy
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
November 15, 2018 (Actual)
Study Completion Date
December 1, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Xu Siqi

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
BACKGROUND: Few researches have manifested that intravenous (IV) lidocaine or dexmedetomidine decreased the incidence of postoperative nausea and vomiting (PONV). The investigators investigated whether IV lidocaine plus dexmedetomidine infusion could better reduce the incidence of PONV after laparoscopic hysterectomy. METHODS: One hundred and twenty women with elective laparoscopic hysterectomy were randomly divided into two groups: patients in the lidocaine combined with dexmedetomidine group (LD group, n=60) received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine (0.5 μg/kg loading, 0.4 μg/kg/h infusion) respectively. Patients in the control group (CON group, n=60) received the equal volume of saline. Primary outcome was the incidence of the first 48 h nausea, vomiting and PONV after surgery. The secondary outcomes included perioperative propofol and remifentanil consumption, postoperative fentanyl requirement, Ramsay sedation score, and bradycardia during post-anaesthesia care unit (PACU) stay.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lidocaine, Dexmedetomidine, Nausea and Vomiting, Postoperative
Keywords
Lidocaine, Dexmedetomidine, Postoperative nausea and vomiting, laparoscopic hysterectomy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Effect of IV lidocaine and dexmedetomidine on PONV
Arm Type
Experimental
Arm Title
Effect of IV saline on PONV
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
lidocaine and dexmedetomidine IV
Intervention Description
Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
Intervention Type
Drug
Intervention Name(s)
saline IV
Intervention Description
Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
Primary Outcome Measure Information:
Title
postoperative nausea
Description
Our primary outcome was the incidence of nausea during the 0-2 hours after surgery
Time Frame
0-2 hours after surgery
Title
postoperative nausea
Description
Our primary outcome was the incidence of nausea during the 2-24 hours after surgery
Time Frame
2-24 hours after surgery
Title
postoperative nausea
Description
Our primary outcome was the incidence of nausea during the 24-48 hours after surgery
Time Frame
24-48 hours after surgery
Title
postoperative vomiting
Description
Our primary outcome was the incidence of vomiting during the 0-2 hours after surgery
Time Frame
0-2 hours after surgery
Title
postoperative vomiting
Description
Our primary outcome was the incidence of vomiting during the 2-24 hours after surgery
Time Frame
2-24 hours after surgery
Title
postoperative vomiting
Description
Our primary outcome was the incidence of vomiting during the 24-48 hours after surgery
Time Frame
24-48 hours after surgery
Title
postoperative nausea and vomiting (PONV)
Description
Our primary outcome was the incidence of PONV during the 0-2 hours after surgery
Time Frame
0-2 hours after surgery
Title
postoperative nausea and vomiting (PONV)
Description
Our primary outcome was the incidence of PONV during the 2-24 hours after surgery
Time Frame
2-24 hours after surgery
Title
postoperative nausea and vomiting (PONV)
Description
Our primary outcome was the incidence of PONV during the 24-48 hours after surgery
Time Frame
24-48 hours after surgery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical statusⅠand Ⅱ Aged 40-55 years Scheduled for elective laparoscopic hysterectomy Exclusion Criteria: History of allergy to local anesthetics Severe respiratory disease Renal or hepatic insufficiency History of preoperative opioids medication and psychiatric preoperative bradycardia preoperative atrioventricular block Subjects who experienced severe hypotension (mean arterial pressure [MAP] <60 mmHg) or bradycardia (heart rate [HR] <40 bpm), urticaria, or arrhythmia during lidocaine and dexmedetomidine infusion period
Facility Information:
Facility Name
Department of Anqing Hospital Anesthesiology
City
Anqing
State/Province
Anhui
ZIP/Postal Code
246000
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Lidocaine Plus Dexmedetomidine Infusion on PONV

We'll reach out to this number within 24 hrs